GlassScriptPhysician profile
Cynthia M Scheibe
NPI 1700821238
$647.16
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $85.70 · 2021: $43.14.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $180.79 | 2019-2020 | |
| Novo Nordisk INC | $64.38 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.25 | 2019-2021 | |
| Abbvie INC. | $45.93 | 2019 | |
| Esperion Therapeutics, INC. | $41.87 | 2020-2021 | |
| Glaxosmithkline, LLC. | $40.04 | 2019-2020 | |
| Amgen INC. | $39.20 | 2019-2020 | |
| Astellas Pharma US INC | $38.06 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $37.79 | 2019-2020 | |
| Allergan, INC. | $29.81 | 2019 | |
| Lilly USA, LLC | $28.88 | 2019 | |
| Tris Pharma INC | $13.23 | 2019 | |
| Pfizer INC. | $12.62 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.41 | 2019 | |
| Shire North American Group INC | $10.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Scheibe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.